AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:12 2024-04-30 am EDT			5-day change	1st Jan Change
12,062 ^GBX	+0.32%		+7.22%	+13.79%

10:19pm	FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	MT
06:01pm	Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	MT

ASTRAZENECA : Barclays gives a Buy rating

January 25, 2023 at 02:44 am EST

Barclays analyst Emily Field maintains his Buy rating on the stock. The target price has been raised from GBX 12500 to GBX 13500.

Latest news about AstraZeneca PLC

FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	04:19pm	MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	12:01pm	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	11:51am	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	11:01am	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	10:50am	MT
ASTRAZENECA : Deutsche Bank gives a Neutral rating	09:34am	ZD
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
European Equities Close Mixed in Monday Trading; Economic Sentiment Falls in April; Lawsuit Dents Deutsche Bank Shares	Apr. 29	MT
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	Apr. 29	MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement	Apr. 29	MT
ASTRAZENECA : JP Morgan maintains a Buy rating	Apr. 29	ZD
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow	Apr. 29	CI
Deutsche Bank likes Frasers; Barclays cuts JD	Apr. 29	AN
AstraZeneca makes progress with Truqap and Enhertu cancer treatments	Apr. 29	AN
AstraZeneca: CHMP green light for Truqap + Faslodex	Apr. 29	CF
AstraZeneca: new positive data for Enhertu	Apr. 29	CF
FTSE 100 continues record run boosted by Anglo American, AstraZeneca	Apr. 29	RE
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study	Apr. 29	MT
AstraZeneca's Truqap Plus Faslodex Breast Cancer Treatment Bags EU Approval Recommendation	Apr. 29	MT
Hipgnosis Songs Fund backs new Blackstone bid	Apr. 29	AN
ASTRAZENECA : DZ Bank sticks Neutral	Apr. 26	ZD
ASTRAZENECA : UBS keeps a Sell rating	Apr. 26	ZD
ASTRAZENECA : Deutsche Bank remains Neutral	Apr. 26	ZD
ASTRAZENECA : Gets a Buy rating from Barclays	Apr. 26	ZD
Barclays Raises AstraZeneca PT, Affirms at Overweight	Apr. 26	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-29 - Roadshow - Day 2

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

150.9 USD

Average target price

164.3 USD

Spread / Average Target

+8.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.79%	234B
ELI LILLY AND COMPANY	+34.00%	664B
NOVO NORDISK A/S	+29.29%	567B
JOHNSON & JOHNSON	-7.75%	354B
MERCK & CO., INC.	+18.53%	330B
ABBVIE INC.	+4.95%	286B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.89%	148B
PFIZER, INC.	-11.01%	145B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Barclays gives a Buy rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals